IPO
iOnctura B.V., a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces the closing of a EUR 15 million Series A financing.
Heidelberg Pharma AG announced that it has secured a financing commitment from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany
Voluntary public share buyback offer against cash payment in a purchase price range of EUR 1.60 to EUR 1.85 per share
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models
Sensyne Health plc, the British Clinical AI technology company, announces its Interim Results for the 6 months ended 31 October 2019.
Evotec SE announced an increase in its profitability guidance for the financial year 2019 after the preliminary completion of the latest evaluation of the Company’s financial performance.
The funds will allow the company to accelerate the development of its chemotherapy drug candidate targeting solid tumors
2019 BioGenerator highlights include eight first-time investments and new companies relocating to St. Louis
The FY20 Defense Appropriations Act provides funding to the Department of Defense Peer Reviewed Medical Research Program to support medical research projects of clear scientific merit and direct relevance to military health.
Xyall BV has been identified as a next-generation global innovator in molecular pathology, winning Series A seed investment of €5 million from investment partners Sioux Technologies, BOM Brabant Ventures, the Netherlands Enterprise Agency and other private investors.
PRESS RELEASES